Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
PALL trial (UCART19): what clinicians have said so far
Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia
- NCT02808442 ↗
- Completed
- Institut de Recherches Internationales Servier
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on PALL (UCART19 in paediatric relapsed/refractory B-cell acute lymphoblastic leukemia) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PALL so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukaemia
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia
- Interventions
- UCART19
- Arms
- UCART19 · Experimental
- Enrollment
- 13
- Primary outcomes
- Incidence and Severity of Adverse Events
- Sponsor
- Institut de Recherches Internationales Servier with ADIR, a Servier Group company
- Start
- Jun 3, 2016
- Primary completion
- Sep 17, 2020
- Results posted
- No
- Registry record
- NCT02808442 · updated Oct 8, 2021
Publications
linked from the registry- Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Boissel N, Maus MV, Frigault MJ, Baruchel A, Mohty M, Gianella-Borradori A, Binlich F, Balandraud S, Vitry F, Thomas E, Philippe A, Fouliard S, Dupouy S, Marchiq I, Almena-Carrasco M, Ferry N, Arnould S, Konto C, Veys P, Qasim W; UCART19 Group. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020 Dec 12;396(10266):1885-1894. doi: 10.1016/S0140-6736(20)32334-5. PubMed 33308471
- Li YR, Zhu Y, Fang Y, Lyu Z, Yang L. Emerging trends in clinical allogeneic CAR cell therapy. Med. 2025 Aug 8;6(8):100677. doi: 10.1016/j.medj.2025.100677. Epub 2025 May 13. PubMed 40367950